Compared to Estimates, AMN Healthcare (AMN) Q3 Earnings: A Look at Key Metrics
The headline numbers for AMN Healthcare (AMN) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
AMN Stock Slips Despite Q2 Earnings & Revenue Beat, Margins Down
AMN Healthcare tops second-quarter 2025 earnings and revenue forecasts, but margins and segment sales face continued pressure.
AMN Healthcare Services, Inc. (AMN) Q2 2025 Earnings Call Transcript
AMN Healthcare Services, Inc. (NYSE:AMN ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Brian M. Scott - CFO & COO Caroline Sullivan Grace - President, CEO & Director Randle G.
Compared to Estimates, AMN Healthcare (AMN) Q2 Earnings: A Look at Key Metrics
The headline numbers for AMN Healthcare (AMN) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
AMN Healthcare Services (AMN) Tops Q2 Earnings and Revenue Estimates
AMN Healthcare Services (AMN) came out with quarterly earnings of $0.3 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.98 per share a year ago.
Analysts Estimate AMN Healthcare Services (AMN) to Report a Decline in Earnings: What to Look Out for
AMN Healthcare (AMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will AMN Healthcare (AMN) Beat Estimates Again in Its Next Earnings Report?
AMN Healthcare (AMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
AMN Stock Gains Post Latest Deals With symplr to Boost Operations
AMN Healthcare sells Smart Square to symplr for $75 million and forms a new technology partnership aimed at boosting scheduling efficiency.
AMN Is Cheap After The Sale Of Symplr
AMN Healthcare is undervalued, trading below $900 million market cap, with strong free cash flow and recent strategic moves to reduce net debt. The sale of Symplr and board expertise in M&A position AMN for further portfolio optimization and potential value-unlocking transactions. Despite recent goodwill impairments and cautious analyst outlooks, AMN's financial initiatives and management actions could attract renewed investor interest.
What Makes AMN Healthcare (AMN) a New Buy Stock
AMN Healthcare (AMN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AMN Healthcare: Demand For Therapy And Imaging Specialties, And Undervalued
AMN Healthcare is undervalued, trading at 3.02x FWD cash flow, with strong demand in therapy and imaging specialties supporting future growth. AI investments and normalization post-COVID-19 are expected to enhance service offerings and drive free cash flow improvements in the coming years. Debt reduction has lowered interest expenses, and a large stock repurchase program signals management's confidence in the company's intrinsic value.
AMN Stock Gains Following Q1 Earnings & Revenue Beat, Margins Down
AMN Healthcare's dismal results in all its segments led to a soft overall first-quarter 2025 performance.
